USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
ZEN-BIO, INC.
Address:
P.O. BOX 13888
3200 CHAPEL HILL-NELSON BLVD.
RTP, NC 27709-
Phone:
N/A
URL:
N/A
EIN:
156194016
DUNS:
799863261
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $2,232,771.00 9
SBIR Phase II $5,518,745.00 4
STTR Phase I $518,888.00 2

Award List:

Commercialization of Human Visceral Adipocytes

Award Year / Program / Phase:
2003 / SBIR / Phase I
Award Amount:
$100,000.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): The US is experiencing an epidemic rise in obesity [1] and related co-morbidities, such as type 2 diabetes. Epidemiological studies demonstrate that these co-morbidities are specifically correlated with visceral (intra-abdominal) fat deposition. To elucidate this… More

Commercialization of Human Visceral Adipocytes

Award Year / Program / Phase:
2005 / SBIR / Phase II
Award Amount:
$961,578.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): The US is experiencing an epidemic rise in obesity and related co-morbidities such as type II diabetes. Epidemiological studies demonstrate that these co-morbidities are specifically correlated with visceral (intra-abdominal) fat deposition. To elucidate this… More

Commercialization of Human Omental Mesothelial Cells for Research

Award Year / Program / Phase:
2007 / SBIR / Phase I
Award Amount:
$86,730.00
Agency:
HHS
Principal Investigator:
Yolanda R. Leacurrie
Abstract:
DESCRIPTION (provided by applicant): Mesothelial cells have been found to be pivotal in tumor metastasis, peritoneal dialysis, and inflammatory response. These cells are specialized epithelial cells that line the peritoneal, pericardial, and pleural caviti es and internal organs presenting a barrier… More

Commercialization of a Human Myocyte and Adipocyte Co-Culture System

Award Year / Program / Phase:
2007 / SBIR / Phase I
Award Amount:
$184,782.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): The well documented rise in obesity over the past two decades correlates with increased incidence rates of metabolic and cardiovascular disease. In response to the associated reduced life expectancy and expensive health problems the NIH has established an… More

Commercialization of Human Mammary Basal / Luminal Cell System for Research

Award Year / Program / Phase:
2008 / SBIR / Phase I
Award Amount:
$206,649.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Breast cancer is the second most common cancer among women. Roughly 180,000 women in the U.S. will be diagnosed with malignant breast cancer in 2007-some 40,000 will die. The majority of breast cancers originate in the lobular or ductal cells of the… More

Commercialization of a Human Myocyte and Adipocyte Co-Culture System

Award Year / Program / Phase:
2008 / SBIR / Phase II
Award Amount:
$1,383,212.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): The dramatic rise in obesity within the U.S. over the past two decades has led to an increase in Type 2 diabetes and related health disorders. The National Institutes of Health has responded by establishing a task force devoted to accelerating the progress in… More

Botannical Extract Library Screeninig with Human ADAS Cells

Award Year / Program / Phase:
2008 / STTR / Phase I
Award Amount:
$228,954.00
Agency:
HHS
Principal Investigator:
Research Institution:
N/A
RI Contact:
N/A
Abstract:
DESCRIPTION (provided by applicant): This Phase I STTR proposal has been substantially revised in response to the Study Section review. The proposal was written in response to the NIH Director's newly released roadmap that encourages collaboration betwee n corporate and academic institutions to… More

Commercialization of Human Mesothelial Cells for Research

Award Year / Program / Phase:
2009 / SBIR / Phase II
Award Amount:
$1,888,394.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Mesothelial cells have been found to be pivotal in tumor metastasis, peritoneal dialysis, and inflammatory response. These cells are specialized epithelial cells that line the peritoneal, pericardial, and pleural caviti es and internal organs presenting a barrier… More

Diabetes Therapies from Adipose Derived Stem Cells

Award Year / Program / Phase:
2010 / SBIR / Phase I
Award Amount:
$363,202.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Diabetes affects the lives of hundreds of millions of people worldwide and the incidence rate is continuing to rise. About 8% of the US population is estimated to have Type 1 or Type 2 diabetes, with the prevalence of T ype 2 diabetes increasing with the rise in… More

Commercialization of Human Mammary Basal / Luminal Cell System for Research

Award Year / Program / Phase:
2010 / SBIR / Phase II
Award Amount:
$1,285,561.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Breast cancer is the second most common cancer among women. Roughly 190,000 women in the U.S. will be diagnosed with breast cancer in 2009, and 40,000 will die. The majority of breast cancers originate in the lobular or ductal cells of the milk-producing glands.… More

Alternative human cell-based models of fatty liver disease

Award Year / Program / Phase:
2010 / SBIR / Phase I
Award Amount:
$227,197.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Obesity and Type 2 diabetes affect the lives of millions of people worldwide, add significantly to health-related expenditures, and are seemingly unmanageable health issues, since rates of occurrence are steadily increa sing. In parallel with the increasing… More

Development of a human skeletal muscle cell-based high throughput screen for musc

Award Year / Program / Phase:
2011 / SBIR / Phase I
Award Amount:
$251,144.00
Agency:
HHS
Principal Investigator:
Bentley Cheatham – 919-547-0692
Abstract:
DESCRIPTION (provided by applicant): Skeletal muscle wasting is a serious condition prevalent in the aging population (sarcopenia) and in a variety of specific diseases. This condition results in loss of muscle function through impaired muscle regeneration, resulting in an increase in falls and… More

Selective Fyn kinase inhibitors for treatment of metabolic disease

Award Year / Program / Phase:
2011 / SBIR / Phase I
Award Amount:
$350,681.00
Agency:
HHS
Principal Investigator:
Bentley Cheatham – 919-547-0692
Abstract:
DESCRIPTION (provided by applicant): Metabolic diseases such as type 2 diabetes (T2D), obesity and their related co-morbidities have reached epidemic proportions worldwide. While progress continues to be made into the molecular mechanisms involved in bothobesity and T2D, the identification and… More

Development of a Drug Discovery Platform for Human Islets

Award Year / Program / Phase:
2012 / SBIR / Phase I
Award Amount:
$462,386.00
Agency:
HHS
Principal Investigator:
Sarah A. Compton – 919-547-0692
Abstract:
DESCRIPTION (provided by applicant): Diabetes and diabetes-related co-morbidities are at epidemic proportions and an enormous burden to our healthcare system. Although there has been significant progress in defining the causative factors and molecular mechanisms involved in both type 1 and type 2… More

Identification of potent and selective GLI1 inhibitors

Award Year / Program / Phase:
2013 / STTR / Phase I
Award Amount:
$289,934.00
Agency:
HHS
Principal Investigator:
Kevin P. Williams – 919-530-7726
Research Institution:
NORTH CAROLINA CENTRAL UNIVERSITY
RI Contact:
Abstract:
DESCRIPTION (provided by applicant): Characterization of human tumor samples and cell lines in combination with inhibitor studies in animal models has established a central role for the Hh pathway in a vast array of cancer types, including small-cell lung, pancreatic, oesophageal, prostate, breast,… More